Combining two drugs may tackle bladder cancer that resists standard therapy

NCT ID NCT04179162

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This trial investigates whether combining two drugs—BCG and gemcitabine—can safely and effectively treat a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC) that has come back after previous BCG treatment. Participants receive BCG directly into the bladder once a week for several weeks, along with gemcitabine twice a week in four cycles. The study first tests different doses of gemcitabine to find the safest level, then measures how many people are cancer-free six months after starting treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BCG (bacillus Calmette-Guérin) and gemcitabine
What this could lead to: If successful, this combination could offer a new treatment option for people whose bladder cancer has stopped responding to standard BCG therapy.
What could go wrong: This is an early-phase trial with a small number of participants, so the combination may not prove effective or may cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)

Contacts and locations

Locations

Hartford Healthcare (Data Collection)

Hartford, Connecticut, 06102, United States
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Commack (Limited Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.